Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

68.85USD
16 Aug 2018
Change (% chg)

$1.48 (+2.20%)
Prev Close
$67.37
Open
$67.50
Day's High
$69.00
Day's Low
$67.37
Volume
4,368,435
Avg. Vol
3,040,410
52-wk High
$69.00
52-wk Low
$52.83

Latest Key Developments (Source: Significant Developments)

Perrigo Expands Otc Growth Strategy With Rx-To-Otc Switch Licensing For Nasonex®
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Perrigo Company Plc ::PERRIGO EXPANDS OTC GROWTH STRATEGY WITH RX-TO-OTC SWITCH LICENSING FOR NASONEX®.FINANCIAL TERMS OF THE LICENSING AGREEMENT WERE NOT DISCLOSED.UNDER TERMS OF AGREEMENT, CO HOLDS RIGHTS TO MARKET, SELL, DISTRIBUTE A NON-PRESCRIPTION VERSION OF NASONEX(®) OTC IN THE UNITED STATES .AGREEMENT WITH SUBSIDIARY OF MERCK FOR EXCLUSIVE RIGHTS IN UNITED STATES TO PURSUE REGULATORY APPROVAL FOR NON-PRESCRIPTION, OTC NASONEX NASAL SPRAY.  Full Article

Express Scripts Announces New Recommendations "Tackling High Drug Prices"
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Express Scripts Holding Co ::SAYS ANNOUNCES NEW RECOMMENDATIONS "TACKLING HIGH DRUG PRICES".SAYS IN 2019, CO'S NATIONAL PREFERRED FORMULARY (NPF) TO PROVIDE ACCESS TO 3,886 MEDICATIONS.SAYS AMONG CHANGES TO NPF THAT TAKE EFFECT JAN. 1 ARE 48 NEW FORMULARY EXCLUSIONS.SAYS NEW FORMULARY EXCLUSIONS HAVE 22 DRUGS THAT HAVE LOW-COST GENERIC ALTERNATIVES.SAYS NEW FORMULARY EXCLUSIONS HAVE 12 INSTANCES OF COMPETITION WHERE DRUGS HAVE SAME ACTIVE INGREDIENT, BUT EXCLUDED DRUG HAS HIGHER NET COST.SAYS NEW FORMULARY EXCLUSIONS HAVE 11 SPECIALTY DRUGS THAT HAVE LOWER-COST BRAND OR BIOSIMILAR ALTERNATIVE WITH LOWER LIST PRICE.SAYS FOR TREATMENT OF HEPATITIS C, 2019 NPF WILL PREFER ZEPATIER AND HARVONI, EPCLUSA, AND VOSEVI IN PLACE OF MAVYRET.SAYS IN HIV CLASS, 2019 NPF WILL PREFER SYMFI AND SYMFI LO OVER ATRIPLA, WHICH WILL BE EXCLUDED.SAYS CHANGES IN 2019 NATIONAL PREFERRED FORMULARY WILL SAVE PLANS AN ESTIMATED $3.2 BILLION.SAYS ABOUT 0.2 PERCENT OF MEMBERS ENROLLED IN AN NPF PLAN WILL SEE A CHANGE IN 2019.  Full Article

Selumetinib Granted Orphan Designation In Europe For Neurofibromatosis Type 1
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Merck & Co Inc ::SELUMETINIB GRANTED ORPHAN DESIGNATION IN EUROPE FOR NEUROFIBROMATOSIS TYPE 1.MERCK - EMA GRANTED ORPHAN DESIGNATION TO SELUMETINIB, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1.  Full Article

Sutro Biopharma Announces $85.4 Million Series E Round
Thursday, 26 Jul 2018 

July 26 (Reuters) - Sutro Biopharma ::SUTRO BIOPHARMA ANNOUNCES $85.4 MILLION SERIES E ROUND.SUTRO BIOPHARMA - MERCK, KNOWN AS MSD OUTSIDE UNITED STATES AND CANADA, HAS MADE AN INVESTMENT AND HAS MADE A COMMITMENT TO A FUTURE INVESTMENT.SUTRO BIOPHARMA - FINANCING WAS LED BY SAMSARA BIOCAPITAL AND SURVEYOR CAPITAL & SUPPORTED BY ALTA PARTNERS, AMGEN VENTURES, CELGENE & OTHERS.  Full Article

Merck Sets Quarterly Dividend Of $0.48/Share
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Merck & Co Inc ::SETS QUARTERLY DIVIDEND OF $0.48 PER SHARE.  Full Article

FDA Accepts Supplemental Biologics License Application For Merck's Keytruda As Adjuvant Therapy In Advanced Melanoma
Monday, 25 Jun 2018 

June 25 (Reuters) - Merck & Co Inc ::FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) AS ADJUVANT THERAPY IN ADVANCED MELANOMA.MERCK & CO INC - FDA GRANTED A PRESCRIPTION DRUG USER FEE ACT (PDUFA), OR TARGET ACTION, DATE OF FEBRUARY 16, 2019.  Full Article

Merck And Premier Collaborate To Help Reduce Clostridium Difficile Infection
Thursday, 31 May 2018 

May 31 (Reuters) - Merck & Co Inc ::MERCK AND PREMIER INC. COLLABORATING TO HELP REDUCE CLOSTRIDIUM DIFFICILE (C. DIFF) INFECTION.MERCK - FINANCIAL TERMS OF COLLABORATION WERE NOT DISCLOSED.  Full Article

Eisai Says FDA Has Extended Action Date For sNDA For Lenvatinib
Friday, 25 May 2018 

May 24 (Reuters) - Merck & Co Inc ::EISAI AND MERCK PROVIDE UPDATE ON SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR LENVATINIB IN FIRST-LINE UNRESECTABLE HEPATOCELLULAR CARCINOMA.EISAI - FDA HAS INDICATED THAT EXTENSION OF PRESCRIPTION DRUG USER FEE ACT DATE IS NEEDED TO ALLOW ADDITIONAL TIME FOR REVIEW OF THE APPLICATION.EISAI SAYS FDA HAS EXTENDED ACTION DATE FOR SNDA FOR LENVATINIB FOR POTENTIAL FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA.EISAI - WORKING CLOSELY WITH FDA TO SUPPORT CONTINUED REVIEW OF THE APPLICATION.  Full Article

Merck Sets Quarterly Dividend Of $0.48/Share
Tuesday, 22 May 2018 

May 22 (Reuters) - Merck & Co Inc ::SETS QUARTERLY DIVIDEND OF $0.48 PER SHARE.  Full Article

FDA Issues Alert On Use Of Keytruda/Tecentriq For Patients With Urothelial Cancer, Have Low Expression Of PD-L1
Friday, 18 May 2018 

May 18 (Reuters) - FDA::U.S. FDA - ISSUES ALERT ABOUT DECREASED SURVIVAL ASSOCIATED WITH THE USE OF KEYTRUDA (PEMBROLIZUMAB) OR TECENTRIQ (ATEZOLIZUMAB).U.S. FDA SAYS THERE WAS NO CHANGE IN THE ADVERSE EVENT PROFILE OF KEYTRUDA OR TECENTRIQ.FDA - MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCS’ RECOMMENDATIONS.U.S. FDA SAYS MONOTHERAPY ARMS REMAIN OPEN ONLY TO PATIENTS WHOSE TUMORS HAVE PD-L1 HIGH STATUS.U.S. FDA - COMBINATION ARMS AND THE CHEMOTHERAPY ARMS OF BOTH STUDIES ALSO REMAIN OPEN.FDA - ISSUED ALERT ON KEYTRUDA/TECENTRIQ AS MONOTHERAPY FOR PATIENTS WITH UROTHELIAL CANCER WHO HAVE NOT RECEIVED PRIOR THERAPY, HAVE LOW EXPRESSION OF PD-L1.  Full Article